Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Organisation › Details

Redvax GmbH

Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of CMV and a further undisclosed field. *

	Start	2014-11-20 established
	Group	Pfizer (Group)
	Predecessor	Redbiotec AG
	Industry	vaccine, HCMV (human cytomegalovirus vaccine)
	Industry 2	vaccine

	Region	Schlieren ZH
	Country	Switzerland
	Street	23 Wagistr.
	City	8952 Schlieren ZH
		Address record changed: 2016-05-01

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Pfizer (Group)

[1] AstraZeneca plc. (9/20/23). "Press Release: Alexion Completes Purchase and Licence Agreement for Early-stage Rare Disease Gene Therapy Portfolio from Pfizer"....
[2] CureVac N.V.. (5/19/23). "Press Release: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech". Tübingen....
[3] BioNTech AG. (3/14/23). "Press Release: Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years". New York & Mainz....
[4] Seagen Inc.. (3/13/23). "Press Release: Pfizer Invests $43 Billion to Battle Cancer. Pfizer to Acquire Seagen for $229 per Seagen Share in Cash". New York, NY & Bothell, WA....
[5] BioNTech SE. (2/10/23). "Press Release: Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program". New York, NY & Mainz....
[6] Anokion S.A.. (10/18/22). "Press Release: Anokion Announces $35 Million Equity Investment from Pfizer". Cambridge, MA & Lausanne....
[7] CytoReason Ltd.. (9/20/22). "Press Release: CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development". Tel Aviv....
[8] Capstan Therapeutics, Inc.. (9/14/22). "Press Release: Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering". San Diego, CA & Philadelphia, PA....
[9] BioNTech SE. (9/1/22). "Press Release: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union". New York, NY & Mainz....
[10] BioNTech SE. (8/31/22). "Press Release: Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older". New York, NY & Mainz....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]